BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 10653869)

  • 21. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies.
    Pavletic ZS; Bishop MR; Tarantolo SR; Martin-Algarra S; Bierman PJ; Vose JM; Reed EC; Gross TG; Kollath J; Nasrati K; Jackson JD; Armitage JO; Kessinger A
    J Clin Oncol; 1997 Apr; 15(4):1608-16. PubMed ID: 9193360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood versus marrow hematopoietic allogeneic graft.
    Robinet E; Lapierre V; Tayebi H; Kuentz M; Blaise D; Tiberghien P
    Transfus Apher Sci; 2003 Aug; 29(1):53-9. PubMed ID: 12877895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
    J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
    Millot F; Esperou H; Bordigoni P; Dalle JH; Michallet M; Michel G; Bourhis JL; Kuenz M; Blaise D; Garban F; Plouvier E; Rome A; Guilhot J; Guilhot F
    Bone Marrow Transplant; 2003 Nov; 32(10):993-9. PubMed ID: 14595387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donor-recipient incompatibility at CD31-codon 563 is a major risk factor for acute graft-versus-host disease after allogeneic bone marrow transplantation from a human leucocyte antigen-matched donor.
    Balduini CL; Frassoni F; Noris P; Klersy C; Iannone AM; Bacigalupo A; Giorgiani G; Di Pumpo M; Locatelli F
    Br J Haematol; 2001 Sep; 114(4):951-3. PubMed ID: 11564091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion.
    Sehn LH; Alyea EP; Weller E; Canning C; Lee S; Ritz J; Antin JH; Soiffer RJ
    J Clin Oncol; 1999 Feb; 17(2):561-8. PubMed ID: 10080600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients.
    Mehta J; Powles R; Kulkarni S; Treleaven J; Singhal S
    Bone Marrow Transplant; 1997 Jul; 20(2):129-35. PubMed ID: 9244416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of unrelated cord blood transplantation and HLA-matched sibling hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in advanced stage.
    Zheng C; Tang B; Yao W; Tong J; Zhu X; Song K; Geng L; Liu H; Sun Z
    Biol Blood Marrow Transplant; 2013 Dec; 19(12):1708-12. PubMed ID: 24060407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation.
    Giralt S; Escudier S; Kantarjian H; Deisseroth A; Freireich EJ; Andersson BS; O'Brien S; Andreeff M; Fisher H; Cork A
    N Engl J Med; 1993 Sep; 329(11):757-61. PubMed ID: 7688862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease].
    Sun AN; Wu DP; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Fu ZZ; Ma X; Han Y; He GS; Chen SN; Xue SL; Zhao Y
    Ai Zheng; 2006 Aug; 25(8):1019-22. PubMed ID: 16965686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The addition of allogeneic peripheral blood-derived progenitor cells to bone marrow for transplantation: results of a randomised clinical trial.
    Szer J; Curtis DJ; Bardy PG; Grigg AP
    Aust N Z J Med; 1999 Aug; 29(4):487-93. PubMed ID: 10868525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected].
    Klingemann HG; Grigg AP; Wilkie-Boyd K; Barnett MJ; Eaves AC; Reece DE; Shepherd JD; Phillips GL
    Blood; 1991 Dec; 78(12):3306-11. PubMed ID: 1742491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Société Française de Greffe de Moelle (SFGM).
    Jourdan E; Maraninchi D; Reiffers J; Gluckman E; Rio B; Jouet JP; Michallet M; Molina L; Archimbaud E; Harousseau JL; Ifrah N; Attal M; Guilhot F; Kuentz M; Guyotat D; Pico JL; Dauriac C; Legros M; Dreyfus F; Bordigoni P; Leblond V; Gratecos N; Varet B; Auzanneau C; Blaise D
    Bone Marrow Transplant; 1997 May; 19(9):875-81. PubMed ID: 9156260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse.
    Ustün C; Arslan O; Beksaç M; Koç H; Gürman G; Ozçelik T; Yilmaz B; Ilhan O; Akan H; Ozcan M; Demirer T; Uysal A; Konuk N; Arat M; Dilek I; Celebi H; Coskun HS
    Biol Blood Marrow Transplant; 1999; 5(1):28-35. PubMed ID: 10232738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current thinking in the management of leukaemia.
    Szer J
    Aust Fam Physician; 1994 Aug; 23(8):1500-5. PubMed ID: 7526835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Peripheral blood stem cell transplantation for 53 patients with malignant hematologic diseases].
    Xie XS; Wan DM; Sun H; Sun L; Liu LX; Jiang ZX
    Ai Zheng; 2007 Apr; 26(4):403-6. PubMed ID: 17430661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic blood cell transplantation without posttransplant colony-stimulating factors in patients with hematopoietic neoplasm: a phase II study.
    Rosenfeld C; Collins R; Piñeiro L; Agura E; Nemunaitis J
    J Clin Oncol; 1996 Apr; 14(4):1314-9. PubMed ID: 8648389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Allogeneic hematopoietic transplantation with stem cells extracted from peripheral blood].
    Kusminsky G; Foncuberta MC; Aversa L; Drelichman G; Freigeiro D; Burgos R; Irrazabal C; Gonzalez G; Dictar M; Niborski R; Kohan A; Sanchez Avalos JC
    Medicina (B Aires); 2000; 60(2):179-87. PubMed ID: 10962806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up of recipients of allogeneic bone marrow grafts reveals no progressive telomere shortening and provides no evidence for haematopoietic stem cell exhaustion.
    de Pauw ES; Otto SA; Wijnen JT; Vossen JM; van Weel MH; Tanke HJ; Miedema F; Willemze R; Roelofs H; Fibbe WE
    Br J Haematol; 2002 Feb; 116(2):491-6. PubMed ID: 11841457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.